Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
1.500
-0.070 (-4.46%)
At close: Feb 23, 2026, 4:00 PM EST
1.530
+0.030 (2.00%)
After-hours: Feb 23, 2026, 6:02 PM EST

Chemomab Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-13.95-24.22-27.65-12.48-5.95
Depreciation & Amortization
0.050.070.060.030.02
Stock-Based Compensation
0.621.493.212.020.13
Change in Accounts Receivable
-0.490.9-0.06-2.06-0.1
Change in Accounts Payable
0.15-1.170.351.180.07
Change in Other Net Operating Assets
-1.77-0.683.72-1.070.59
Operating Cash Flow
-15.39-23.61-20.37-12.37-5.24
Capital Expenditures
--0-0.07-0.24-0.04
Sale of Property, Plant & Equipment
---1-
Investment in Securities
2.315.8819.6-45.95-0.02
Other Investing Activities
---0-
Investing Cash Flow
2.315.8819.53-45.19-0.06
Issuance of Common Stock
9.873.50.4158.651.25
Repurchase of Common Stock
---1.22--
Other Financing Activities
---2.43-
Financing Cash Flow
9.873.5-0.8161.074.75
Net Cash Flow
-3.22-4.23-1.653.51-0.55
Free Cash Flow
-15.39-23.61-20.44-12.61-5.28
Free Cash Flow Per Share
-3.43-8.04-7.18-4.86-3.09
Cash Income Tax Paid
--0.19-0.35--
Levered Free Cash Flow
-10.86-15.49-10.87-6.07-2.56
Unlevered Free Cash Flow
-10.86-15.49-10.87-6-2.56
Change in Working Capital
-2.11-0.954.01-1.950.56
Updated Nov 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q